Segment and Geographic Information (Details) - USD ($) $ in Millions		3 Months Ended																					6 Months Ended		12 Months Ended
		Dec. 31, 2017		Sep. 30, 2017	[3]	Jul. 01, 2017	[4]	Apr. 01, 2017	[5]	Dec. 31, 2016	Dec. 31, 2016		Oct. 01, 2016	[7]	Jul. 02, 2016	[8]	Apr. 02, 2016	[9]	Dec. 31, 2015		Sep. 26, 2015	[11]	Dec. 31, 2015	Dec. 27, 2014	Dec. 31, 2017	Dec. 31, 2016	Jun. 27, 2015
Segment Reporting Information [Line Items]
Net sales	[1]																						$ 2,632.2		$ 4,946.2	$ 5,280.6	$ 4,227.1
Operating income																							$ 67.6	$ 289.7	$ 598.2	$ (1,999.7)	$ 672.5
Operating income %																							2.60%		12.10%	(37.90%)	15.90%
Assets		$ 11,628.8								$ 13,870.1	$ 13,870.1								$ 19,349.6				$ 19,349.6		$ 11,628.8	$ 13,870.1	$ 19,591.9
Capital expenditures																							77.8		88.6	106.2	137.0
Property and equip, net		833.1								870.1	870.1								886.2				886.2		833.1	870.1	932.4
Depreciation/amortization																							182.4		444.8	457.0	258.7
Change in financial assets		0.7	[2]	$ 2.6		$ 38.7		$ (17.1)		1,100.0	1,115.6	[6]	$ 377.4		$ 910.8		$ 204.4		116.6	[10]	$ (173.8)		(57.3)	$ (46.9)	24.9	2,608.2	(78.5)
CHCA
Segment Reporting Information [Line Items]
Net sales																							1,251.5		2,429.9	2,507.1	2,478.8
CHCA | Cough/Cold/Allergy/Sinus
Segment Reporting Information [Line Items]
Net sales	[12]																						234.6		483.7	454.6	455.6
CHCA | Analgesics
Segment Reporting Information [Line Items]
Net sales	[12]																						173.1		349.8	343.5	375.7
CHCA | Gastrointestinal
Segment Reporting Information [Line Items]
Net sales	[12]																						195.8		340.0	335.4	384.0
CHCA | Infant nutritionals
Segment Reporting Information [Line Items]
Net sales																							200.2		413.9	427.0	383.8
CHCA | Smoking cessation
Segment Reporting Information [Line Items]
Net sales																							147.5		297.2	308.5	284.5
CHCA | Vitamins, minerals and dietary supplements
Segment Reporting Information [Line Items]
Net sales	[12]																						105.8		45.4	160.4	183.5
CHCA | Animal health
Segment Reporting Information [Line Items]
Net sales																							62.3		141.3	143.7	157.0
CHCA | Other CHCA
Segment Reporting Information [Line Items]
Net sales	[12],[13]																						132.2		358.6	334.0	254.7
CHCI
Segment Reporting Information [Line Items]
Net sales																							833.0		1,491.0	1,652.2	704.6
CHCI | Branded OTC
Segment Reporting Information [Line Items]
Net sales																							665.9		1,174.0	1,349.2	368.4
CHCI | Other CHCI
Segment Reporting Information [Line Items]
Net sales	[14]																						167.1		317.0	303.0	336.2
RX | Generic prescription drugs
Segment Reporting Information [Line Items]
Net sales																							502.6		969.7	1,042.8	936.0
Other | Active pharmaceutical ingredients
Segment Reporting Information [Line Items]
Net sales																							45.1		55.6	78.5	107.7
Ireland
Segment Reporting Information [Line Items]
Net sales	[1]																						11.4		30.4	89.1	7.2
Property and equip, net		4.6								2.7	2.7								1.3				1.3		4.6	2.7
Unites States
Segment Reporting Information [Line Items]
Net sales	[1]																						1,686.2		3,272.3	3,353.0	3,303.2
Property and equip, net		538.3								556.6	556.6								555.0				555.0		538.3	556.6
Europe
Segment Reporting Information [Line Items]
Net sales	[1]																						758.2		1,313.2	1,493.0	576.4
Property and equip, net		155.6								144.6	144.6								157.2				157.2		155.6	144.6
ISRAEL
Segment Reporting Information [Line Items]
Property and equip, net		81.5								114.3	114.3								115.7				115.7		81.5	114.3
All other countries
Segment Reporting Information [Line Items]
Net sales	[1],[15]																						176.4		330.3	345.5	$ 340.3
Property and equip, net		53.1								51.9	51.9								57.0				$ 57.0		$ 53.1	$ 51.9
Walmart | Net sales | Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage																							13.00%		13.00%	13.00%	16.00%
Operating Segments | CHCA
Segment Reporting Information [Line Items]
Net sales																							$ 1,251.5		$ 2,429.9	$ 2,507.1	$ 2,478.8
Operating income																							$ 209.2		$ 445.0	$ 399.8	$ 381.9
Operating income %																							16.70%		18.30%	15.90%	15.40%
Assets		3,786.8								3,351.3	3,351.3								3,384.8				$ 3,384.8		$ 3,786.8	$ 3,351.3	$ 3,763.8
Capital expenditures																							38.0		39.5	59.1	76.8
Property and equip, net		512.7								528.3	528.3								540.9				540.9		512.7	528.3	556.8
Depreciation/amortization																							60.9		115.2	119.1	108.4
Change in financial assets																							0.0		0.0	0.0	0.0
Operating Segments | CHCI
Segment Reporting Information [Line Items]
Net sales	[16]																						833.0		1,491.0	1,652.2	704.6
Operating income	[16]																						$ (148.5)		$ 12.5	$ (2,087.4)	$ 38.2
Operating income %	[16]																						(17.80%)		0.80%	(126.30%)	5.40%
Assets	[16]	5,029.0								4,795.2	4,795.2								7,083.5				$ 7,083.5		$ 5,029.0	$ 4,795.2	$ 7,163.0
Capital expenditures	[16]																						26.3		27.5	23.7	13.1
Property and equip, net	[16]	180.9								167.2	167.2								179.5				179.5		180.9	167.2	176.8
Depreciation/amortization	[16]																						81.9		223.7	210.0	72.5
Change in financial assets	[16]																						0.0		0.0	0.0	0.0
Operating Segments | RX
Segment Reporting Information [Line Items]
Net sales																							502.6		969.7	1,042.8	936.0
Operating income																							$ 181.9		$ 307.6	$ (0.2)	$ 364.7
Operating income %																							36.20%		31.70%	0.00%	39.00%
Assets		2,813.0								2,646.4	2,646.4								2,738.0				$ 2,738.0		$ 2,813.0	$ 2,646.4	$ 2,373.4
Capital expenditures																							12.1		21.6	20.4	41.0
Property and equip, net		139.5								129.7	129.7								118.5				118.5		139.5	129.7	113.0
Depreciation/amortization																							34.3		100.1	120.1	65.7
Change in financial assets																							0.0		0.0	0.0	0.0
Operating Segments | Specialty Sciences
Segment Reporting Information [Line Items]
Net sales																							0.0		0.0	0.0	0.0
Operating income																							$ (6.5)		$ 0.0	$ (201.2)	$ (17.6)
Operating income %																							0.00%		0.00%	0.00%	0.00%
Assets		0.0								2,775.8	2,775.8								5,930.2				$ 5,930.2		$ 0.0	$ 2,775.8	$ 6,040.7
Capital expenditures																							0.0		0.0	0.0	0.5
Property and equip, net		0.0								0.4	0.4								0.0				0.0		0.0	0.4	0.0
Depreciation/amortization																							0.0		0.0	0.0	1.5
Change in financial assets																							(57.3)		24.9	2,608.2	(78.5)
Operating Segments | Other
Segment Reporting Information [Line Items]
Net sales																							45.1		55.6	78.5	107.7
Operating income																							$ (19.5)		$ 8.7	$ 6.1	$ 26.8
Operating income %																							(43.30%)		15.60%	7.80%	24.90%
Assets		0.0								301.4	301.4								213.1				$ 213.1		$ 0.0	$ 301.4	$ 251.0
Capital expenditures																							1.4		0.0	3.0	5.6
Property and equip, net		0.0								44.5	44.5								47.3				47.3		0.0	44.5	85.8
Depreciation/amortization																							5.3		5.8	7.8	10.6
Change in financial assets																							0.0		0.0	0.0	0.0
Unallocated
Segment Reporting Information [Line Items]
Net sales																							0.0		0.0	0.0	0.0
Operating income																							$ (149.0)		$ (175.6)	$ (116.8)	$ (121.5)
Operating income %																							0.00%		0.00%	0.00%	0.00%
Assets		0.0								0.0	0.0								0.0				$ 0.0		$ 0.0	$ 0.0	$ 0.0
Capital expenditures																							0.0		0.0	0.0	0.0
Property and equip, net		$ 0.0								$ 0.0	$ 0.0								$ 0.0				0.0		0.0	0.0	0.0
Depreciation/amortization																							0.0		0.0	0.0	0.0
Change in financial assets																							$ 0.0		$ 0.0	$ 0.0	$ 0.0

[1] The net sales by geography is derived from the location of the entity that sells to a third party.

[2] (5) Includes unusual litigation charge reversal of $0.2 million.Year Ended December 31, 2016FirstQuarter (2) SecondQuarter (3) ThirdQuarter (4) FourthQuarter (5)Net sales$1,347.3 $1,340.5 $1,261.6 $1,331.2Gross profit$533.1 $546.5 $484.5 $487.7Change in financial assets$204.4 $910.8 $377.4 $1,115.6Net loss$(529.2) $(534.3) $(1,590.2) $(1,359.1)Loss per share(1): Basic$(3.70) $(3.73) $(11.10) $(9.48)Diluted$(3.70) $(3.73) $(11.10) $(9.48)Weighted average shares outstanding Basic143.2 143.2 143.3 143.4Diluted143.2 143.2 143.3 143.4

[3] Includes held-for-sale impairment charges of $3.3 million, and fixed asset impairment charges of $4.0 million.

[4] Includes intangible asset impairment charges of $18.5 million, changes in financial assets of $38.7 million, and loss on early debt extinguishment of $135.2 million.

[5] Includes IPR&D impairment charges of $12.2 million, gain on certain divestiture of $21.8 million, and restructuring charges of $38.7 million.

[6] Includes intangible asset impairment charges of $378.6 million, goodwill impairment charge of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million.

[7] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charge of $737.9 thousand, and held-for-sale impairment charges of $10.2 million.

[8] Includes held-for-sale impairment charges of $10.5 million and change in financial assets of $910.8 million.

[9] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.

[10] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.

[11] Includes Mylan defense-related fees of $15.6 million.

[12] Includes net sales from our OTC contract manufacturing business.

[13] Consists primarily of feminine hygiene, diabetes care, dermatological care, branded OTC, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCA segment.

[14] Consists primarily of liquids licensed products, cough/cold/allergy, analgesics, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCI segment.

[15] Includes revenue generated primarily in Israel, Mexico, Australia, and Canada.

[16] CHCI includes Omega activity subsequent to March 30, 2015.